Next Week Could Be Big for $IVOB
October 30th, 2009 at 6:53 am Posted by The Dean
Earlier this week, $IVOB announced the clinical results of the initial INVO procedures performed at the CECOFLES Fertility Center in Columbia. The Dean believes the news of a 36% success rate is huge for $IVOB because it provides clinical evidence that the company’s INVO procedure is just as effective as conventional IVF.
Over the past few months, the CollegeStock Community has learned that $IVOB has expanded their territory into 15 countries in Latin and South America. Distribution through The Daxley Group makes $IVOB‘s INVOcell device accessible to an estimated 9 million infertile couples in this region. And, The Dean thinks that one of these countries could be of particular interest for $IVOB.
Chile has been in the news lately because of the country’s unusually high infertility rates. In a study of 1,800 couples reporting to have problems conceiving, 85% of men and 75% of women showed signs of infertility. Typically, infertility rates are higher in women but the results of this study show otherwise.
Similar to the male infertility problems The Dean has taught the CollegeStock Community about in China, Chilean men reportedly have lower sperm counts because of drinking alcohol, smoking and obesity. The article covering this study suggests that these findings are consistent with a survey which showed that Chilean women are having fewer children than they want to—33% less.
Also contributing to this problem, another source reports that Chilean women are attempting pregnancy at later points in their lives. In fact, the Chilean Fertility Association reports the number of women ages 35 to 40 receiving infertility treatment has increased from 35% to 47% in the past 3 years.
Taking into consideration the average age of 35 in the clinical trials in Columbia and the fact that the new mother in Pakistan was 40 years old, The Dean believes $IVOB‘s INVO procedure could become a desirable treatment for women in this age group
While unfortunate for infertile couples, the findings in Chile could mean more good news to come for $IVOB. And to make $IVOB‘s new results and these studies even more meaningful, $IVOB President and Chief Scientific Officer Dr. Claude Ranoux will be speaking and holding workshops at the Procrearte Infertility Network Meeting in Argentina next week.
The Dean thinks this is an exciting time for $IVOB and 150 reproductive health specialists in the region will be there to hear the results of Columbia’s clinical trials.
As if that’s not potentially BIG enough, at virtually the same time, $IVOB CEO Kathleen Karloff will be in Cairo, Egypt announcing more results—data from a clinical study on the first 100 INVO procedures performed in the Middle East.
Over the past 3 months, $IVOB has made significant steps towards giving birth to The Dean’s Billion Dollar Baby. In fact, $IVOB has already gained 500% for Honors Students and could certainly see more to come.
Dean – what makes you so confident all the news is not already out on IVOB and November 4-6 material won’t simply repeat what we already know. financial news readers do not ordinarily follow developments in Egypt and S.America, so how that attract any new shareholders? The stock has already run 500% in anticipation of INVOcell actually working – so now that we know it does – why buy the stock here?
@Pack my interview with CEO Katie Karloff (recorded on video) will shed a lot more light on the situation. They are less than 18 months away from FDA approval as a medical device.